Recommendations for accreditation of laboratories in molecular biology of hematologic malignancies

Volume 73, issue 5, Septembre-Octobre 2015

Authors
Pascale Flandrin-Gresta 1 *
Pascale Cornillet 2
Sandrine Hayette 3
Nathalie Gachard 4
Sylvie Tondeur 5
Carole Mauté 6
Jean-Michel Cayuel 6

Pour le Groupe des biologistes moléculaires des hémopathies malignes (GBMHM)
1 Laboratoire d'hématologie, Hôpital Nord, CHU Saint-Étienne, Saint-Étienne, France
2 Laboratoire d'hématologie, Reims, France
3 Laboratoire d'hématologie, Lyon, France
4 Laboratoire d'hématologie, Limoges, France
5 Laboratoire d'hématologie, Montpellier, France
6 Laboratoire d'hématologie, Paris, France

* Tiéres à part

Key words: accreditation, hematological malignancy, molecular biology

DOI : 10.1684/abc.2015.1067
Page(s) : 595-630
Published in: 2015

Over recent years, the development of molecular biology techniques has improved the hematological diseases diagnostic and follow-up. Consequently, these techniques are largely used in the biological screening of these diseases; therefore the Hemato-oncology molecular diagnostics laboratories must be actively involved in the accreditation process according the ISO 15189 standard. The French group of molecular biologists (GBMHM) provides requirements for the implementation of quality assurance for the medical molecular laboratories. This guideline states the recommendations for the pre-analytical, analytical (methods validation procedures, quality controls, reagents), and post-analytical conditions. In addition, herein we state a strategy for the internal quality control management. These recommendations will be regularly updated.
Tables

Tableau 1

Tableau 2

Tableau 3
As the molecular basis for activation of clotting in hematologic malignancies becomes better elucidated, we anticipate the development of drugs that will target both the malignant process and the resultant THS.

Correspondence Frederick R. Rickles, MD, FACP, The George Washington University, 3910 Highwood Ct, NW, Washington DC 20007; phone (202) 965-2356; fax (202) 965-0708; [email protected].

From Music to Molecular Biology. Tell the readers a bit about your background before joining SLU. I wasn’t one of these people who dreamed of a career in medicine from an early age. I also have my own laboratory, which is focused on a novel approach to identifying new anticancer drugs by making alterations in lipid metabolism in cancer cells, altering the lipid composition of cell membranes to which cancer cells are particularly sensitive. This approach limits cancer cell growth, kills cancer cells, and also acts to reverse chemotherapy drug resistance.

Newer Therapies. Currently, few therapeutic strategies exist for patients with hematologic malignancies who relapse after allogeneic hematopoietic stem cell transplant. Are we making progress in this tough clinical scenario?